InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
DewDiligence PremiumMember
05/22/19 11:17 AM
profile icon
eddy2 Free
05/18/16 10:07 AM
profile icon
power_forward Free
08/04/15 9:42 AM
profile icon
eddy2 Free
08/03/15 2:31 PM
profile icon
sidedraft Free
06/13/15 2:21 PM
profile icon
eddy2 Free
06/13/15 2:01 PM
profile icon
eddy2 Free
06/13/15 2:00 PM
profile icon
98040 Free
06/11/15 2:12 PM
profile icon
sidedraft Free
06/11/15 10:34 AM
profile icon
armo Free
06/09/15 12:06 PM
profile icon
power_forward Free
06/09/15 11:00 AM
profile icon
98040 Free
06/07/15 2:55 PM
profile icon
armo Free
06/05/15 11:51 AM
profile icon
98040 Free
06/05/15 11:48 AM
profile icon
98040 Free
06/04/15 6:35 PM
profile icon
98040 Free
05/31/15 1:51 PM
profile icon
Qmark Terminated
05/31/15 1:41 PM
profile icon
98040 Free
05/28/15 2:35 PM
profile icon
eddy2 Free
05/05/15 2:02 PM
profile icon
eddy2 Free
05/02/15 11:49 AM
profile icon
98040 Free
04/30/15 12:01 PM
profile icon
98040 Free
04/29/15 11:37 PM
profile icon
eddy2 Free
04/29/15 8:55 AM
profile icon
eddy2 Free
04/22/15 8:53 AM
profile icon
eddy2 Free
04/22/15 8:49 AM
profile icon
98040 Free
04/15/15 4:20 PM
profile icon
eddy2 Free
04/15/15 4:04 PM
profile icon
kraken17 Free
04/15/15 3:09 PM
profile icon
98040 Free
04/13/15 2:58 PM
profile icon
eddy2 Free
04/12/15 11:55 AM
profile icon
eddy2 Free
04/11/15 4:33 PM
profile icon
stockanalyze Free
04/08/15 10:32 PM

Dendreon Corp fka DNDNQ RSS Feed

Followers
223
Posters
917
Posts (Today)
0
Posts (Total)
12660
Created
07/17/05
Type
Free
Moderators

DENDREON  http://www.dendreon.com/

Dendreon Corporation (NASDAQ: DNDN) is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization, and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering, and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010 and by the European Medicines Agency in 2013. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and has manufacturing facilities in Georgia and California.
 

 

PAVING A NEW PATH FOR TREATING CANCER

PROVENGE® (sipuleucel-T) is the first autologous cellular immunotherapy to receive FDA approval for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. PROVENGE is designed to take the body’s own immune cells and reprogram them to attack advanced prostate cancer.

Important Safety Information

PROVENGE full Prescribing Information

For more information about PROVENGE, please visit www.PROVENGE.com.

US Health Care Professionals can visit the Medical Affairs Web site to submit a request online.

http://www.dendreon.com/products/provenge/manufacturing/
http://www.dendreon.com/products/provenge/scientific_publications/
 

PATIENT RESOURCES

The Patient Resources section includes information about patient access, clinical trials and patient information.

For Questions about PROVENGE® (sipuleucel-T), contact Dendreon ON Call:
Phone: 877-336-3736
Fax: 877-556-3737

http://www.dendreon.com/patient_resources/patient_access/
 

CLINICAL TRIALS

Dendreon has several ongoing clinical trials, including:

Sipuleucel-T Clinical Trials

P10-1

  • An Open-Label, Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated with Sipuleucel-T on Dendreon Study P-11
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

P10-2

  • A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Non-Metastatic Prostate Cancer and a Rising Prostate Specific Antigen After Primary Therapy.
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

P10-3 (called PROCEED)

  • A Registry of Sipuleucel-T in Men with Advanced Prostate Cancer (called PROCEED) to Further Evaluate Safety and Survival Associated with Sipuleucel-T
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

P11-1

  • An Open-Label Study of Sipuleucel-T in European Men with Metastatic, Castrate Resistant Prostate Cancer
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov

P11-3

  • A Randomized, Open-Label, Phase 2 Trial of Sipuleucel-T with Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men with Metastatic Castrate Resistant Prostate Cancer
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov

P11-4 (PRIME)

  • Immune Monitoring Protocol in Men with Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov

P12-1

  • An Observational Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Metastatic Disease in Castrate-Resistant Prostate Cancer
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov

P12-2

  • A Randomized, Open-Label, Phase 2 Trial Examining Combination Therapy with Sipuleucel-T and Enzalutamide in Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer.
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov

Additional ACI Product Candidate Clinical Trials

N10-1 (called Neu-ACT)

  • A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

    

PATIENT INFORMATION

To find out more about cancer and specifically prostate cancer, we have provided a list of patient-focused cancer organizations.

Pipeline

POTENTIAL NEW CANCER THERAPIES ON THE HORIZON

Investigational product candidates in the Dendreon pipeline include:

 

Investor Relations

Stock Quote (NASDAQ: DNDN)
Price:
2.04
Change:
+ 0.03
Volume:
1,783,600
4:00 PM ET on Jun 13, 2014
Delayed at least 20 minutes.
Provided by eSignal.
Stock price graph
3 Mo.   6 Mo.   1 Yr.

Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.

View all »   RSSRecent Releases

http://investor.dendreon.com/stockquote.cfm
http://investor.dendreon.com/media.cfm
http://investor.dendreon.com/events.cfm
http://investor.dendreon.com/sec.cfm
http://investor.dendreon.com/analysts.cfm
http://investor.dendreon.com/annuals.cfm
http://investor.dendreon.com/investorkit.cfm
http://investor.dendreon.com/alerts.cfm


$DNDN Charts:





 
 

 

Board Info
Posts Today
0
Posts (Total)
12660
Posters
917
Moderators
New Post